Research ExplorerPublicationsLong-term outcomes after adjuvant treatment of sequential ve...

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

Standard

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. / Mackey, J R; Pieńkowski, T; Crown, J; Sadeghi, S; Martin, M; Chan, A; Saleh, M; Sehdev, S; Provencher, L; Semiglazov, V; Press, M F; Sauter, G; Lindsay, M; Houé, V; Buyse, M; Drevot, P; Hitier, S; Bensfia, S; Eiermann, W.

In: ANN ONCOL, Vol. 27, No. 6, 06.2016, p. 1041-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mackey, JR, Pieńkowski, T, Crown, J, Sadeghi, S, Martin, M, Chan, A, Saleh, M, Sehdev, S, Provencher, L, Semiglazov, V, Press, MF, Sauter, G, Lindsay, M, Houé, V, Buyse, M, Drevot, P, Hitier, S, Bensfia, S & Eiermann, W 2016, 'Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial', ANN ONCOL, vol. 27, no. 6, pp. 1041-7. https://doi.org/10.1093/annonc/mdw098

APA

Mackey, J. R., Pieńkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M. F., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., & Eiermann, W. (2016). Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. ANN ONCOL, 27(6), 1041-7. https://doi.org/10.1093/annonc/mdw098

Vancouver

Mackey JR, Pieńkowski T, Crown J, Sadeghi S, Martin M, Chan A et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. ANN ONCOL. 2016 Jun;27(6):1041-7. https://doi.org/10.1093/annonc/mdw098

Bibtex

@article{143167ebd1a9401b8cbba309c8890e2d,
title = "Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial",
abstract = "BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety.PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC → T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography.RESULTS: The 10-year DFS rates were 66.5% in the AC → T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC → T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC → T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy.CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC → T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity.TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208.",
keywords = "Journal Article",
author = "Mackey, {J R} and T Pie{\'n}kowski and J Crown and S Sadeghi and M Martin and A Chan and M Saleh and S Sehdev and L Provencher and V Semiglazov and Press, {M F} and G Sauter and M Lindsay and V Hou{\'e} and M Buyse and P Drevot and S Hitier and S Bensfia and W Eiermann",
note = "{\textcopyright} The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2016",
month = jun,
doi = "10.1093/annonc/mdw098",
language = "English",
volume = "27",
pages = "1041--7",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

AU - Mackey, J R

AU - Pieńkowski, T

AU - Crown, J

AU - Sadeghi, S

AU - Martin, M

AU - Chan, A

AU - Saleh, M

AU - Sehdev, S

AU - Provencher, L

AU - Semiglazov, V

AU - Press, M F

AU - Sauter, G

AU - Lindsay, M

AU - Houé, V

AU - Buyse, M

AU - Drevot, P

AU - Hitier, S

AU - Bensfia, S

AU - Eiermann, W

N1 - © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2016/6

Y1 - 2016/6

N2 - BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety.PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC → T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography.RESULTS: The 10-year DFS rates were 66.5% in the AC → T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC → T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC → T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy.CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC → T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity.TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208.

AB - BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety.PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC → T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography.RESULTS: The 10-year DFS rates were 66.5% in the AC → T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC → T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC → T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy.CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC → T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity.TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208.

KW - Journal Article

U2 - 10.1093/annonc/mdw098

DO - 10.1093/annonc/mdw098

M3 - SCORING: Journal article

C2 - 26940688

VL - 27

SP - 1041

EP - 1047

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 6

ER -